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Abstract
The role of bevacizumab-based maintenance after first-line bevacizumab-based induction treatment of met-
astatic colorectal cancer was evaluated in a meta-analysis of 3 randomized trials. Maintenance treatment with
bevacizumab with or without fluoropyrimidines improved progression-free survival and showed a trend toward
improved overall survival.
Background: The administration and intensity of bevacizumab-based maintenance therapy after induction treatment
with bevacizumab is still a matter of debate. Thus, the present meta-analysis and an indirect comparison were per-
formed to clarify these issues. Patients and Methods: Trials evaluating a separately defined “maintenance phase,”
with randomization after the induction phase, were selected. Three trials of maintenance with bevacizumab with or
without a fluoropyrimidine (CAIRO3, SAKK 41/06, and AIO KRK 0207) were analyzed regarding the effect on
progression-free survival (PFS) and overall survival (OS) of any maintenance therapy compared with observation alone
and different maintenance intensities (bevacizumab with or without fluoropyrimidine) compared with observation alone
and between each other. Results:Maintenance with bevacizumab with or without fluoropyrimidine after bevacizumab-
based induction treatment for 4 to 6 months significantly improved PFS (hazard ratio [HR], 0.57; 95% confidence
interval [CI], 0.43-0.75; P ¼ .0004) and showed a trend toward prolonged OS (HR, 0.89; 95% CI, 0.78-1.02; P ¼ .09)
compared with observation alone. The effect on PFS increased with the intensity of the maintenance regimen (HR,
0.72; 95% CI, 0.60-0.85 for single-agent bevacizumab vs. HR, 0.45; 95%, CI 0.39-0.51 for combination therapy, both
compared to observation alone). In contrast, the HRs for OS remained in the same range. A similarly improved PFS
(HR, 0.63; 95% CI, 0.50-0.79) was shown for the more intensive maintenance therapy (bevacizumab and fluoropyr-
imidine) compared with bevacizumab alone. Conclusion: Bevacizumab-based maintenance therapy after induction
chemotherapy with bevacizumab significantly improves PFS and showed a trend toward prolonged OS and should
thus be considered, in particular, in patients with a response to induction treatment.
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Colorectal cancer (CRC) is one of the most commonly diagnosed
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Effect of Application and Intensity of Bevacizumab-based Maintenance Therapyafter curative intent treatment, resulting in the relatively high overall
mortality rate associated with CRC.2
Several drugs as single agents or in various combinations are
available to treat mCRC, including fluoropyrimidines (5-
fluorouracil [5-FU], capecitabine), irinotecan, oxaliplatin, the
vascular endothelial growth factor (VEGF) antibody bevacizumab,
the epidermal growth factor receptor (EGFR) antibodies cetuximab
and panitumumab for RAS wild-type mCRC, the VEGF receptors 1
and 2 fusion protein aflibercept, and the multitarget tyrosine kinase
inhibitor regorafenib. The current standard first-line treatment is a
combination of a chemotherapy doublet of a fluoropyrimidine with
oxaliplatin and/or irinotecan (FOLFOX [folinic acid, 5-FU, oxali-
platin], CAPOX [capecitabine, oxaliplatin], FOLFIRI [folinic acid,
5-FU, irinotecan] regimens) plus bevacizumab or an EGFR anti-
body (cetuximab or panitumumab) for patients with RAS wild-type
tumors. As a result of recent advances in treatment, median overall
survival (OS) can now be as long as 30 months in selected patient
groups.3-6
The first-line treatment will be the longest treatment phase and is
thus of particular importance regarding the overall treatment strat-
egy. The established standard for many years was continuation of
the initial treatment until the occurrence of progression or unac-
ceptable toxicity. Newer strategies, developed particularly for
oxaliplatin-based regimen, have used a limited concept of “induc-
tion and maintenance,” with several strategies used in addition to
the previous standard of continuation of full treatment until pro-
gression (Table 1). These strategies were initially triggered by the
dose-cumulative neurotoxicity associated with oxaliplatin. In addi-
tion to the sparing of cumulative side effects (and thus improving
patient quality of life), continuation of induction treatment beyond
3 to 6 months in a palliative situation without a chance for sec-
ondary local ablation does not seem to be beneficial. Therefore,
induction/maintenance strategies to date have used a 3- to 6-month
duration of induction chemotherapy, including other regimen than
only FOLFOX. Although intermittent treatment with preplanned
maintenance or full-stop intervals was evaluated in several trials, this
approach has not been widely adopted.7-9 Recent trials allocatedTable 1 Currently Available Maintenance Strategies and
Respective Randomized Trials
Strategy Trials
Partial stop and go with maintenance
Stop most toxic drug (eg, oxaliplatin), apply
maintenance (single-agent 5-fluorouracil,
bevacizumab, or cetuximab or 5-fluorouracil plus
bevacizumab); if feasible, restart induction
treatment at progression
OPTIMOX 2, COIN-B,
CAIRO3, SAKK 41/06,
MACRO, Turkish Oncology
Group - Stop and
Go - Trial, AIO KRK 0207
Stop/restart toxic drug (eg, oxaliplatin) in
preplanned intervals
OPTIMOX 1, CONcePT
Complete stop and go
Stop all drugs after 3 mo, restart at progression,
and stop again after another 3 mo
COIN
Stop/restart all drugs in preplanned intervals GISCAD
Switch maintenance
Introduce new drug into maintenance strategy
(adding erlotinib to bevacizumab maintenance)
DREAM, Nordic ACT
Clinical Colorectal Cancer June 2016patients after 3 to 6 months of induction treatment to different
maintenance strategies and/or observation alone.10-16 These trials all
showed an effect on progression-free survival (PFS) or the respective
alternate endpoints eg, time to failure of strategy or time to second
progression; however, the effect on OS has remained unclear. The
current meta-analysis was performed to compare observation alone
with bevacizumab or bevacizumab and chemotherapy maintenance
after induction chemotherapy in terms of PFS and OS.Patients and Methods
Definition of Analysis and Trial Selection
Pertinent data from published trials (PubMed) and abstracts
presented at selected oncology association meetings (American So-
ciety of Clinical Oncology and European Society for Medical
Oncology/European Cancer Organization) until June 2015 were
systematically searched using MeSH and full-text search terms for
“metastatic colorectal cancer,” “first-line treatment,” or “mainte-
nance treatment.” In addition, the references of all eligible studies
were manually reviewed to find additional relevant studies.
Overall, 9 trials were identified that had compared any mainte-
nance strategy until progression with observation alone or the
continuation of full treatment (Figure 1; Table 2).10-12,14,15,17-19 Of
these, 5 trials were selected for additional analysis, because these
trials evaluated a separately defined “maintenance phase,” with
randomization after the induction phase (OPTIMOX 3/DREAM
[Optimized Leucovorin Fluorouracil Oxaliplatin/Double Inhibition
Reintroduction Erlotinib Avastin Metastatic Colorectal Cancer],
Nordic ACT [Chemotherapy and Avastin Followed by Mainte-
nance Treatment With Avastin þ/ Tarceva], CAIRO 3 [CApe-
citabine, IRinotecan and Oxaliplatin], SAKK 41/07 [Swiss Group
for Clinical Cancer Research], AIO KRK 0207 [Workinggroup
Medical Oncology Colorectal Cancer]). The selected studies were
assessed for potential bias with regard to the randomization
approach, timely parallel enrollment, similarity of treatment groups,
data-driven reporting, analysis population (intent-to-treat [ITT] vs.
other), and other aspects. The OPTIMOX 3/DREAM and Nordic
ACT trials evaluated the addition of erlotinib to bevacizumab
maintenance.10,19 However, erlotinib has not been licensed for
mCRC treatment, and approval, considering the data obtained,
seems unlikely.
To clarify the most relevant issues to date, the 3 trials evaluating
bevacizumab with or without fluoropyrimidine maintenance
(CAIRO 3, SAKK 41/06, and AIO KRK 0207) were selected for
the main analysis because of their similar design (comparison of
bevacizumab-based maintenance with observation alone;
Figure 2).13-15 The combined analysis of these data was performed
to evaluate the following questions:
1. Effect of any bevacizumab-based (with or without chemo-
therapy) maintenance compared with observation alone
2. Effect of bevacizumab maintenance compared with obser-
vation alone
3. Effect of fluoropyrimidine and bevacizumab maintenance
compared with observation alone
4. Indirect comparison of different maintenance intensities
(fluoropyrimidine and bevacizumab compared with bev-
acizumab alone)
Figure 1 Flowchart of Study Selection
Alexander Stein et alTo answer the fourth question regarding the different maintenance
intensities, the 2 single-agent bevacizumab arms (SAKK 41/06 and
AIO KRK 0207) were compared with the 2 fluoropyrimidine andTable 2 Currently Available Randomized Clinical Trials Evaluating D
Strategy Randomization Clinical Trial Induction Regimen
Maintenance vs.
observation
Upfront OPTIMOX 2 FOLFOX
COIN-B FOLFOX þ cetuximab
After induction CAIRO3 CAPOX þ bevacizuma
SAKK 41/06 Chemotherapy þ bevacizu
(32% 5-FU þ Iri; 62%
5-FU þ Oxa)
AIO KRK 0207 5-FU þ Oxa þ bevacizum
Different
maintenance
regimen
After induction OPTMOX 3/DREAM Chemotherapy þ bevacizu
(90% 5-FU þ Oxa; 10%
FOLFIRI)
Nordic ACT Chemotherapy þ bevacizu
Maintenance vs.
continuation of
full treatment
Upfront MACRO CAPOX þ bevacizuma
Turkish Oncology
Group - Stop and
Go - Trial
CAPOX þ bevacizuma
Abbreviations: 5-FU ¼ 5-fluorouracil; CAPOX ¼ capecitabine, oxaliplatin; FOLFIRI ¼ folinic acid,
Oxa ¼ oxaliplatin.bevacizumab arms (AIO KRK 0207 and CAIRO 3). The meta-
analysis of these 3 similarly performed trials was performed to
combine the currently available data and provide a clinically relevantifferent Maintenance Strategies
Maintenance Regimen Patients (n) Comment
5-FU/LV vs. observation 202 Excluded owing to different
maintenance regimen
Cetuximab vs. observation 169 Excluded because no
formal comparison
b Capecitabine þ bevacizumab
vs. observation
558 Included
mab Bevacizumab vs. observation 262 Included
ab Bevacizumab  5-FU/LV or
capecitabine vs. observation
472 Included
mab Bevacizumab vs.
bevacizumab þ erlotinib
452 Excluded owing to use of
bevacizumab in both arms
mab Bevacizumab vs.
bevacizumab þ erlotinib
159
b Bevacizumab vs.
CAPOX þ bevacizumab
470 Comparison of full
treatment continuation vs.
maintenance
b Capecitabine þ bevacizumab
vs. CAPOX þ bevacizumab
123
5-FU, irinotecan; FOLFOX ¼ folinic acid, 5-FU, oxaliplatin; Iri ¼ irinotecan; LV ¼ leucovorin;
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Figure 2 Overview of Maintenance Trials Evaluating Bevacizumab With or Without Fluoropyrimidine (FP) Maintenance
Abbreviations: Beva ¼ bevacizumab; cont. ¼ continuous; CTx ¼ cetuximab; mCRC ¼ metastatic colorectal cancer; OX ¼ oxaliplatin; qm ¼ every month.
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therapy after induction treatment with bevacizumab and
chemotherapy.
The 4 remaining trials had randomized patients upfront (before
induction treatment) and thus could not be analyzed for the effect
of different maintenance strategies, at least not regarding PFS during
maintenance therapy.
Statistical Analysis
The PFS and OS were analyzed in meta-analyses and using an
indirect comparison. All meta-analyses were performed using the
software Review Manager, version 5.3 (The Nordic Cochrane
Centre, The Cochrane Collaboration, Copenhagen, Denmark),
based on the reported hazard ratios (HRs) and 95% confidence
intervals (CIs) from each study using random effects models.20 A
test for heterogeneity was performed to assess for deviations from
homogeneity of the studies and to assess whether the studies could
be summarized in a meta-analysis. If the P value for heterogeneity
was  .20, no proof for heterogeneity was concluded, and a meta-
analysis was performed. With proof of heterogeneity (P < .20),
considerable heterogeneity was concluded, and the studies were not
summarized in a meta-analysis. The cause of heterogeneity was
assessed, and only those studies were combined that did not show
considerable heterogeneity. In addition, an indirect comparison was
performed to compare combination therapy against single-agent
bevacizumab using “observation” as the bridge comparator. The
approach by Bucher et al21 was used to perform the comparisonClinical Colorectal Cancer June 2016according to the meta-analytical results. A 95% CI for the HR < 1
would show statistically significant results in favor of combination
therapy.21 The indirect comparison was performed using Statistical
Analysis Systems, version 9.2 (SAS Institute Inc., Cary, NC).
Results
The 3 studies comparing observation alone with bevacizumab
with or without fluoropyrimidine after induction treatment
(Figure 1), which had been selected for the meta-analyses and in-
direct comparison, were assessed for their potential for bias. All 3
studies were fully published randomized controlled trials with an
adequate randomization approach and timely parallel enrollment.
All 3 studies were open-label studies, and no crossover was allowed.
The reported analyses for the endpoints of PFS and OS were
standard approaches based on the ITT population; thus, data-driven
reporting could be excluded. In the absence of any other aspect, the
potential for bias was assessed as low for the endpoint OS in all 3
studies. Owing to the open-label design of the studies and the
reading of the radiologic images at the study sites and not centrally,
the endpoint PFS was suggested to have a high potential for bias.
Therefore, the PFS results should be interpreted cautiously.
The studies with any active maintenance (bevacizumab with or
without fluoropyrimidine), after bevacizumab-based induction
treatment for 4 to 6 months, showed improved PFS (Figure 3).
However, a meta-analysis showed considerable heterogeneity (P ¼
.0004). Thus, the 3 studies were not combined but were separated
into single-agent bevacizumab and combination bevacizumab and
Figure 3 Progression-free Survival of Maintenance With Bevacizumab With or Without Fluoropyrimidine Versus Observation
Abbreviations: CI ¼ confidence interval; Combi ¼ combination therapy; Mono ¼ monotherapy; SE ¼ standard error.
Alexander Stein et alfluoropyrimidine. In contrast, with regard to mortality, the studies
were not heterogeneous (P ¼ .89). In the meta-analysis, active
maintenance showed a trend toward prolonged OS (HR, 0.89; 95%
CI, 0.78-1.02; P ¼ .09; Figure 4) compared with observation alone
(CAIRO3, SAKK 41/06, and AIO KRK 0207). Maintenance with
single-agent bevacizumab significantly increased PFS (HR, 0.72;
95% CI, 0.60-0.85; P ¼ .0001) and showed a trend toward pro-
longed OS (HR, 0.85; 95% CI, 0.69-1.05; P ¼ .14) compared with
observation alone (see Supplemental Figures 1 and 3 in the online
version). The more intensive maintenance strategy with bev-
acizumab and fluoropyrimidine compared with observation alone
seemed to have a stronger effect on PFS (HR, 0.45; 95% CI, 0.39-
0.51; P < .0001). In contrast, the HRs for OS remained similar to
single agent bevacizumab (HR, 0.92; 95% CI, 0.77-1.09; P ¼ .31;
see Supplemental Figures 2 and 4 in the online version).
Finally, the indirect comparison showed improved PFS (HR,
0.63; 95% CI, 0.50-0.79) for the more intensive maintenance
regimen (bevacizumab and fluoropyrimidine) compared with bev-
acizumab alone. In line with the homogenous results across all
therapy strategies, no effect on OS was found in favor of 1 of these 2
maintenance strategies (HR, 1.08; 95% CI, 0.82-1.42; Figure 5).
The consistency of direct and indirect evidence was assessed using
direct evidence from AIO 0207 and indirect evidence from SAKK
41/06 and CAIRO3. For PFS, heterogeneity was found for the 2
treatment arms (P ¼ .03), suggesting a treatment effect with regard
to the HRs for the combination and mono-strategy (HR combi-
nation, 0.48; 95% CI, 0.37-0.61) versus (HR monotherapy, 0.69;
95% CI, 0.55-0.87; HR combination/HR mono, 0.70; 95% CI,Figure 4 Overall Survival of Maintenance With Bevacizumab With o
Abbreviations: CI ¼ confidence interval; Combi ¼ combination therapy; Mono ¼ monotherapy; SE0.49-0.98). These results are in line with the advantage of the
combination strategy in the indirect comparison of the data from
CAIRO3 and SAKK 41/06 (HR, 0.57; 95% CI, 0.42-0.78). For
OS, no deviance from homogeneity was found between the 2
treatment arms compared with observation (P ¼ .62) within the
AIO 0207 study (HR combination, 0.99; 95% CI, 0.71-1.38; vs.
HR monotherapy, 0.88; 95% CI, 0.63-1.23) with a ratio of the
HRs of 1.13 (95% CI, 0.70-1.80). This is in line with the findings
from the indirect comparison of CAIRO3 and SAKK 41/06 (HR,
1.07; 95% CI, 0.76-1.51). Overall, a consistency of the direct and
indirect evidence can be concluded for both endpoints evaluated.
For the combined switch maintenance with erlotinib and bev-
acizumab, a favorable outcome in terms of PFS (HR, 0.77; 95% CI,
0.64-0.93; P ¼ .006) and a trend toward a prolonged OS (HR,
0.89; 95% CI, 0.73-1.08; P ¼ .24) was noted (see Supplemental
Figures 5 and 6 in the online version).
Discussion
The results from the current meta-analysis have clearly shown
significant benefits in terms of PFS and a trend toward prolonged
OS in favor of a bevacizumab-based maintenance compared with
observation alone after 4 to 6 months of induction treatment.
Although the intensity of maintenance bevacizumab and fluo-
ropyrimidine versus single-agent bevacizumab showed an effect on
PFS, no difference in OS was noted. Similar trends were found in
the randomized AIO KRK 0207 trial comparing observation with
single-agent bevacizumab and bevacizumab plus fluoropyr-
imidine.15 Thus, both options can be considered after 4 to 6r Without Fluoropyrimidine Versus Observation
¼ standard error.
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Figure 5 Indirect Comparison of Bevacizumab (BC) and Fluoropyrimidine Versus Bevacizumab
Abbreviations: CI ¼ confidence interval; Combi ¼ combination therapy; HR ¼ hazard ratio; OS ¼ overall survival; PFS ¼ progression-free survival.
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significant benefit in terms of PFS, the more intensive regimen
might be chosen if durable disease control is of importance (eg,
widespread and symptomatic disease at the initial presentation).
Because of the missing OS benefit, observation alone is a valid
treatment approach, in particular in terms of the relevant treatment
cost for bevacizumab-based maintenance therapy (estimated addi-
tional cost of approximately US$30,000 in the SAKK 41/06 trial).
Regarding the significant benefit for PFS and the noted trend for
OS (HR, 0.89) with well-tolerated treatment administered for 5 to
6 months, maintenance therapy should still be considered. Both
CAIRO3 and AIO KRK 0207 have consistently shown a significant
benefit in terms of OS for those achieving an objective response
(complete or partial response) during induction treatment. In
addition, the RAS/BRAF subgroup analysis of the AIO KRK 0207
suggested that bevacizumab plus fluoropyrimidine maintenance
might be better than single-agent bevacizumab in patients with
mutations. Further research is needed to detect the subgroups that
will benefit from maintenance therapy and to evaluate the cost-
effectiveness of bevacizumab-based maintenance.
Although a significantly better PFS could be shown for the
combination of erlotinib and bevacizumab compared with bev-
acizumab alone, the relatively modest efficacy seems to be out-
weighed by the significant toxicity, specifically rash, diarrhea, and
fatigue.10,19 Therefore, the licensing and consecutive administration
of erlotinib in mCRC maintenance seems unlikely.
The present meta-analysis had several limitations, including using
the published HRs rather than individual patient data.13-15
Furthermore, the heterogeneities in the trial design (superiority in
CAIRO3 and noninferiority in AIO KRK 0207 and SAKK 41/06),
patient inclusion criteria (eg, exclusion of patients with toxic effects
from induction treatment in CAIRO3), and the treatment applied
(eg, differences in induction treatment and fluoropyrimidine
maintenance schedule) should be considered as potential biases. TheClinical Colorectal Cancer June 2016induction treatment was heterogeneous among the trials in terms of
duration, ranging from 4 to 6 months, the use of oxaliplatin (100%
of patients in CAIRO3 and AIO KRK 0207, 62% in SAKK 41/06,
with 31% receiving irinotecan), intensity (7% received induction
treatment with fluoropyrimidine and bevacizumab in the SAKK 41/
06), and the fluoropyrimidine backbone used (capecitabine/oxali-
platin at 100% in CAIRO3 and only 16% in AIO KRK 0207). The
dosage of the fluoropyrimidine-based maintenance regimen differed
between CAIRO3 (capecitabine with 625 mg/m2 twice daily
continuously) and AIO KRK 0207 (capecitabine with 1000 mg/m2
twice daily for 2 weeks, followed by a 1-week break, or 5-FU/leu-
covorin [LV] at a full dosage ranging from 2400 to 3000 mg/m2
continuous infusion for 2 days with or without a bolus every 2
weeks) thus potentially influencing the results of the pooled
intensive maintenance arms.
Additional maintenance strategies (eg, single-agent cetuximab or
5-FU/LV compared with observation alone or bevacizumab-based
maintenance compared with full treatment continuation) could
not be included owing to the upfront randomization.11,12,17,18 The
results from the present analysis do not allow for conclusions
regarding the comparative value of bevacizumab versus fluoropyr-
imidines or the effect of EGFR antibodies in this setting. The
discussed maintenance approach has generally been limited to an
oxaliplatin-based regimen, although a small number of patients
receiving an irinotecan-based induction regimen were included in
the SAKK 41/06 (about 30%) and the OPTIMOX 3/DREAM
trials. In addition to the intermittent treatment approach applied in
the GISCAD trial, the effect of a de-escalation strategy after an
irinotecan-based first-line regimen combined with monoclonal an-
tibodies compared with continuation of full-dose treatment remains
unclear.7
In addition, the endpoint of PFS was considered to have a high
potential for bias owing to the open-label design of all 3 studies and
the assessment of the radiologic images at the study sites and not
Alexander Stein et alcentrally. Also, the indirect comparison had some limitations. The
similarity of the studies was assessed, and no deviance was detected;
however, hidden confounders could have introduced bias into the
results. Owing to the limited number of studies, no sensitivity an-
alyses were performed to assess any confounding. The high potential
for bias for the PFS endpoint also led to relevant uncertainty; thus,
the results should be interpreted with care. The consistency of the
direct and indirect evidence was assessed using the indirect com-
parison and study AIO KRK 0207. No major deviances were found,
suggesting a valid indirect comparison.
Regarding the remaining unresolved issues in maintenance (eg,
patient or regimen selection), the evaluation of new treatment
strategies or agents in the maintenance setting has gained wide-
spread interest in the past years, with a variety of trials currently
ongoing.22
Conclusion
Bevacizumab-based maintenance after induction chemo-
therapy with bevacizumab significantly improves PFS and shows
a favorable trend in prolonging OS. Regarding the lack of a
significant OS benefit, bevacizumab-based maintenance therapy
after induction treatment is not the standard approach for all
patients with mCRC. However, patients achieving an objective
response during bevacizumab-based induction treatment seem to
derive a relevant OS benefit. The intensity of the maintenance
therapy (single-agent bevacizumab or combined with a fluo-
ropyrimidine) only affects PFS. Thus, the more intensive main-
tenance regimens may be limited to patients in need of durable
disease control or those with worse prognostic features (eg, RAS/
BRAF mutation). The decision regarding maintenance therapy
warrants consideration in a shared decision-making process with
the patient considering disease-specific factors (eg, the response to
induction treatment).
Clinical Practice Points
 Regarding the recently achieved long-term survival of patients
with mCRC, continuation of full-dose systemic treatment
throughout the disease course is no longer feasible.
 Different treatment approaches are available after 3 to 6 months
of induction treatment (treatment break, intermittent treatment,
or maintenance).
 Recent data have shown the beneficial effect of bevacizumab-based
maintenance treatment compared with observation alone in terms
of PFS, although the effect on OS is unclear and the intensity of
maintenance treatment remains a matter of debate.
 Bevacizumab-based maintenance therapy after 4 to 6 months of
bevacizumab-based induction treatment significantly improved
PFS (HR, 0.57; 95% CI, 0.43-0.75; P ¼ .0004) and showed
a trend toward prolonged OS (HR, 0.89; 95% CI, 0.78-1.02;
P ¼ .09).
 Improved PFS (HR, 0.63; 95% CI, 0.50-0.79) was shown for
the more intensive maintenance regimen (bevacizumab and
fluoropyrimidine) compared with bevacizumab alone, although
OS remained unaffected (HR, 1.08; 95% CI, 0.82-1.42).
 Because of the limited effect on OS, bevacizumab-based main-
tenance therapy is not the standard treatment approach for all
patients but should be considered for patients with a response toinduction or requiring durable disease control (significant PFS
benefit).
 The addition of fluoropyrimidine to bevacizumab had no effect
on OS; thus, both strategies can be considered if active main-
tenance therapy is chosen.Acknowledgments
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Supplemental Figure 2 Progression-free Survival of Maintenance With Bevacizumab and Fluoropyrimidine Versus Observation
Abbreviations: CI ¼ confidence interval; Combi ¼ combination therapy; SE ¼ standard error.
Supplemental Figure 1 Progression-free Survival of Maintenance With Bevacizumab (Bev) Versus Observation (Obs)
Abbreviations: CI ¼ confidence interval; Mono ¼ monotherapy; SE ¼ standard error.
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Supplemental Figure 4 Overall Survival of Maintenance With Bevacizumab and Fluoropyrimidine Versus Observation
Abbreviations: CI ¼ confidence interval; Combi ¼ combination therapy; SE ¼ standard error.
Supplemental Figure 3 Overall Survival of Maintenance With Bevacizumab Versus Observation
Abbreviations: CI ¼ confidence interval; Mono ¼ monotherapy; SE ¼ standard error.
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Supplemental Figure 6 Overall Survival of Bevacizumab (Bev) Versus Bevacizumab/Erlotinib (Bev/Erlo)
Abbreviations: CI ¼ confidence interval; SE ¼ standard error.
Supplemental Figure 5 Progression-free Survival of Bevacizumab (Bev) Versus Bevacizumab/Erlotinib (Bev/Erlo)
Abbreviations: CI ¼ confidence interval; SE ¼ standard error.
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